lundi 29 septembre 2014

Adding cediranib to chemotherapy improves progression-free survival for metastatic or recurrent cervical cancer, phase II trial shows

For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumor shrinkage and adds a modest improvement in progression-free survival, researchers report.

Adding cediranib to chemotherapy improves progression-free survival for metastatic or recurrent cervical cancer, phase II trial shows

Aucun commentaire:

Enregistrer un commentaire